vaccin
repres
effect
strategi
fight
infecti
diseas
recent
estim
suggest
vaccin
prevent
million
death
everi
year
need
rapid
larg
scale
vaccin
product
epidem
emerg
pathogen
major
challeng
vaccin
develop
includ
effect
vaccin
antigen
divers
versatil
pathogen
success
subvert
host
immun
human
immunodefici
viru
hiv
hepat
c
viru
hcv
malaria
dna
vaccin
overcom
challeng
rel
easi
produc
larg
number
dose
within
short
period
time
stabl
ambient
temperatur
requir
cold
chain
transport
also
consist
lot
excel
safeti
profil
allow
safeti
evalu
regulatori
author
distribut
larg
scale
importantli
dna
vaccin
induc
humor
cellmedi
respons
vaccin
host
although
safe
well
toler
often
poorli
immunogen
inefficaci
human
therefor
recent
studi
advanc
dna
vaccin
focus
effect
deliveri
increas
immunogen
encod
antigen
interest
effect
immun
dna
vaccin
requir
effici
transfect
host
cell
highli
depend
deliveri
rout
use
devic
convent
deliveri
rout
introduc
dna
vaccin
includ
intramuscular
intraderm
subcutan
oral
rout
prefer
deliveri
rout
depend
requir
activ
specif
immun
cell
skin
rich
immun
cell
includ
local
dendrit
cell
dc
natur
killer
nk
cell
therefor
like
favor
site
vaccin
deliveri
attempt
improv
dna
deliveri
made
physic
method
use
gene
gun
electropor
transient
permeabil
cell
membran
effici
transfer
dna
result
increas
vaccin
uptak
skin
muscl
cell
although
method
shown
increas
dna
uptak
requir
optim
achiev
increas
effici
accept
clinic
use
altern
approach
improv
transfect
effici
includ
formul
dna
liposom
nanoparticl
liposom
deliveri
affect
presystem
epitheli
system
barrier
enzymat
degrad
bind
opson
encapsul
dna
nanoparticl
report
increas
dna
uptak
transfect
effici
challeng
use
nanoparticl
dna
includ
encapsul
ineffici
endocytosi
target
cell
toxic
use
genet
adjuv
one
approach
enhanc
immunogen
antigen
use
complement
strategi
eg
dna
deliveri
also
design
improv
immunogen
dna
vaccin
upon
immun
dna
vaccin
target
cell
uptak
dna
endocytosi
transfect
cell
express
dnaencod
protein
antigen
antigenpres
cell
apc
directli
transfect
intracellular
protein
process
immunogen
epitop
present
mhc
class
molecul
directli
stimul
cell
protein
immunogen
releas
transfect
cell
endocytos
andor
phagocytos
apc
present
mhc
class
ii
molecul
activ
naiv
cell
protein
express
stromal
cell
like
keratinocyt
apc
also
indirectli
captur
secret
antigen
crosspres
mhc
class
molecul
stimul
cell
dna
vaccin
cell
specif
vaccin
antigen
undergo
expans
acquir
effector
function
differenti
memori
cell
memori
cell
differenti
effector
memori
cell
upon
reexposur
antigen
abil
dna
vaccin
elicit
cell
immun
thu
depend
activ
apc
present
antigen
mhc
complex
cell
adjuv
serv
import
costimulatori
factor
enhanc
process
brief
review
base
experi
discuss
progress
develop
dna
vaccin
approach
improv
deliveri
genet
adjuv
use
enhanc
immunogen
focu
innov
cytolyt
dna
technolog
develop
patent
laboratori
differ
cytokin
interleukin
chemokin
granulocytemacrophag
colonystimul
factor
gmcsf
costimulatori
molecul
signal
molecul
interferon
regulatori
factor
use
genet
adjuv
dna
vaccin
gene
express
use
stimul
respons
stimul
inclus
gene
encod
cytokin
like
adjuv
dna
vaccin
known
increas
cell
mediat
immun
cmi
howev
bicistron
hiv
dna
encod
elicit
weaker
specif
immun
respons
monocistron
dna
combin
genet
adjuv
like
dna
vaccin
also
use
synergist
effect
level
total
antibodi
antigen
report
phase
iiia
trial
show
coadministr
dna
vaccin
encod
prostat
acid
phosphatas
pap
gmcsf
elicit
papspecif
andor
cell
respons
howev
gmcsf
administ
recombin
protein
class
molecular
chaperon
known
induc
matur
dc
activ
pathway
fusion
vaccin
multipl
myeloma
term
shown
effect
inhibit
target
tumor
increas
surviv
vaccin
mice
elicit
tumorspecif
humor
cellular
immun
respons
howev
dna
vaccin
encod
fuse
target
cervic
intraepitheli
neoplasia
fail
enhanc
signific
cell
respons
phase
clinic
trial
bicistron
dna
encod
membran
bound
secret
protein
use
improv
immunogen
hiv
gag
case
express
driven
weaker
promot
hiv
gag
stronger
cmv
promot
vaccin
design
enhanc
gagspecif
cell
respons
provid
greater
protect
mice
challeng
ecohiv
ecohiv
chimer
viru
contain
envelop
protein
gp
mous
leukemia
viru
rather
hiv
gp
replic
mous
leukocyt
vivo
thu
repres
viabl
mous
challeng
model
earli
assess
hiv
vaccin
propos
mechan
adjuv
tlr
dc
interact
secret
bound
attract
dc
site
antigen
express
follow
dc
matur
present
antigen
mhc
molecul
secret
cytokin
costimulatori
molecul
thu
enhanc
cell
immun
respons
vaccin
antigen
chimer
version
oligomer
domain
chicken
complement
inhibitor
use
produc
oligomer
form
vaccin
antigen
protein
term
form
heptamer
structur
vaccin
protein
use
develop
dna
vaccin
tuberculosi
malaria
hiv
enhanc
humor
andor
cellular
respons
vaccin
dna
vaccin
encod
secret
hiv
tat
tpatat
induc
higher
humor
cellular
respons
improv
protect
ecohiv
challeng
mice
phase
clinic
trial
tuberculosi
vaccin
evalu
vaccin
safe
immunogen
cellular
ifn
humor
mvaspecif
igg
respons
signific
thu
abil
adjuv
enhanc
immunogen
dna
vaccin
human
still
debat
vsv
g
type
iii
viral
fusion
envelop
protein
mediat
fusion
viru
envelop
host
cell
membran
use
fusogen
membran
glycoprotein
fmg
gene
vsv
dna
vaccin
encod
protein
human
papillomaviru
type
shown
enhanc
cell
respons
effect
control
growth
tumor
vsv
g
protein
also
shown
induc
trespons
low
dose
tindepend
respons
higher
dose
fmg
fuse
cell
larg
multinucl
syncytia
kill
nonapoptot
mechan
syncytiosom
releas
membran
present
antigen
effici
dc
fmg
thu
act
adjuv
antigen
express
dna
vaccin
vaccin
mice
hepat
c
viru
hcv
nonstructur
protein
togeth
vsvg
result
increas
frequenc
ifn
effector
memori
tem
cell
dna
vaccin
construct
bicistron
vector
vsvg
coencod
plasmid
hcv
vsvg
express
driven
weaker
promot
stronger
cmv
promot
howev
other
also
report
increas
specif
cmi
immunogen
vsvg
express
differ
plasmid
perforin
prf
pore
form
protein
releas
immun
cell
includ
nk
cell
cytotox
lymphocyt
ctl
prf
protein
oligomer
form
pore
serv
channel
releas
granzym
cytosol
target
cell
suicid
gene
induc
apoptosi
target
cell
use
cancer
therapi
role
apoptot
cell
death
vaccin
whether
immunestimulatori
immunesuppress
debat
recent
novel
dna
technolog
cytolyt
dna
truncat
mous
prf
incorpor
bicistron
dna
vector
act
vaccin
adjuv
differ
recombin
cytolyt
dnaprf
vaccin
rdnaprf
shown
elicit
immun
respons
higher
elicit
canon
dna
vaccin
without
prf
mechan
underli
establish
previou
studi
show
coexpress
hcv
prf
elicit
nonapoptot
cell
death
transfect
cell
whilst
immun
dna
vaccin
increas
cell
mediat
respons
evidenc
increas
respons
elispot
assay
increas
number
polyfunct
tem
cell
simultan
secret
cytolyt
dna
platform
express
immunogen
driven
stronger
promot
allow
suffici
antigen
express
accumul
within
target
cell
follow
nonapoptot
cell
death
due
lesser
express
prf
driven
weaker
promot
thu
balanc
level
antigen
express
time
cell
death
necrosi
consid
mechan
cell
death
prf
evidenc
releas
lactat
dehydrogenas
ldh
low
caspas
activ
ldh
releas
occur
ruptur
cell
membran
secondari
necrosi
contrast
ldh
releas
cell
treat
doxorubicin
proapoptot
drug
cell
transfect
wild
type
prf
prf
mutant
nontox
prf
express
prf
cytolyt
dna
eg
prf
vaccin
thu
result
necrot
cell
death
mediat
receptorinteract
kinas
activ
evidenc
detect
uncleav
cytokeratin
cell
necrosi
releas
damag
associ
molecular
pattern
damp
turn
activ
dc
migrat
site
vaccin
purifi
dc
includ
subset
mice
expos
cell
transfect
ovalbuminprf
result
upregul
costimulatori
molecul
indic
matur
immun
cell
cytolyt
dna
signific
increas
dc
crosspres
dc
upregul
report
mice
vaccin
cytolyt
dna
hiv
gag
prf
compar
canon
dna
vaccin
local
migrat
dc
site
inflamm
take
antigen
endocytosi
also
expos
damp
activ
matur
dc
prime
cell
figur
antigen
crosspresent
dc
cell
shown
increas
number
prolifer
cell
cytolyt
dna
compar
noncytolyt
prf
dna
thu
cytolyt
dna
vaccin
inbuilt
adjuv
enhanc
immunogen
vaccin
immunogen
wherea
immunogen
canon
dna
vaccin
mostli
depend
direct
transfect
dc
lesser
extent
crosspresent
antigen
shed
transfect
cell
andor
deriv
transfect
cell
undergon
spontan
cell
death
sever
studi
establish
dc
expos
necrot
lytic
cell
express
antigen
matur
crosspres
effici
dc
expos
antigen
deriv
cellular
milieu
compris
apoptot
cell
compar
studi
evalu
abil
proapoptot
eg
rotaviru
nonstructur
protein
diphtheria
toxin
subunit
dta
necrot
protein
eg
truncat
prf
enhanc
immunogen
dna
encod
plasmid
dna
vaccin
show
truncat
prf
effect
purpos
howev
caveat
vaccineencod
antigen
need
accumul
significantli
insid
cell
necrosi
occur
follow
express
truncat
prf
order
activ
dc
crosspres
vaccineencod
antigen
rdnaprf
technolog
use
develop
hiv
hcv
dna
vaccin
direct
comparison
effect
cytolyt
prf
apoptot
protein
dta
immunogen
gag
protein
show
prf
activ
dc
effici
evidenc
increas
frequenc
crosspres
dc
upregul
activ
marker
dna
vaccin
prf
dta
driven
promot
immun
mice
dna
vaccin
encod
proapoptot
dta
adjuv
hiv
gag
dta
vaccin
result
decreas
dc
activ
suggest
dtainduc
apoptosi
attenu
immun
respons
furthermor
improv
protect
mous
ecohiv
challeng
model
achiev
rdnaprf
encod
hiv
gag
compar
protect
level
mice
vaccin
canon
gag
dna
vaccin
rdnaprf
vaccin
encod
hcv
protein
coexpress
prf
shown
increas
cmi
mice
pig
compar
coexpress
proapoptot
protein
rotaviru
protein
enterotoxin
elicit
proapoptot
effect
disrupt
mitochondri
membran
activ
studi
show
prf
coexpress
induc
cell
death
necrosi
thu
enhanc
immun
respons
wherea
proapoptot
reduc
respons
importantli
hcv
prf
immunogen
canon
vaccin
pig
demonstr
translat
potenti
cytolyt
dna
vaccin
human
clinic
trial
likewis
shown
multiantigen
hcv
dna
vaccin
encod
genotyp
protein
coexpress
prf
induc
robust
cmi
rang
hcv
ns
protein
compar
coexpress
vsvg
also
show
multiantigen
multigenotyp
hcv
genotyp
dna
cocktail
vaccin
encod
prf
significantli
increas
magnitud
breadth
cmi
respons
genotyp
compar
elicit
singlegenotyp
vaccin
dna
vaccin
still
promis
option
develop
novel
vaccin
strategi
although
mani
advantag
abil
induc
effect
immun
respons
human
requir
protect
challeng
challeng
includ
ineffect
deliveri
poor
uptak
dna
consequ
recent
focu
develop
deliveri
method
andor
inclus
genet
adjuv
genet
adjuv
gener
coexpress
antigen
interest
deliv
differ
plasmid
quest
develop
identifi
effect
genet
adjuv
rang
adjuv
test
vsvg
dta
prf
novel
promis
cytolyt
dna
vaccin
strategi
develop
cytolyt
dna
vaccin
uniqu
base
bicistron
plasmid
abil
coexpress
antigen
prf
balanc
mechan
caus
necrosi
vaccinetransduc
cell
follow
increas
activ
immun
cell
cross
present
vaccin
immunogen
cytolyt
dna
vaccin
encod
nonstructur
protein
hcv
test
enhanc
immunogen
vaccin
antigen
mice
larg
preclin
anim
model
pig
likewis
increas
immunogen
improv
protect
ecohiv
challeng
mice
hiv
gag
prf
demonstr
effect
cytolyt
dna
vaccin
adjuv
provid
effect
costimul
immun
respons
specif
immunogen
may
similar
effect
immunogen
therefor
need
test
efficaci
use
genet
adjuv
prf
produc
suitabl
microenviron
multiplediffer
immunogen
thu
improv
deliveri
immunogen
effect
dna
vaccin
strategi
consider
potenti
develop
dnabas
vaccin
rang
infecti
agent
